《盈警響號》常茂生物(00954.HK)料中期淨利潤下降至1,200萬-1,800萬人幣
常茂生物(00954.HK)公布,集團於截至今年6月30日止六個月很有可能錄得淨利潤約1,200萬元人民幣(下同)至1,800萬元,較去年同期的4,252.8萬元大幅下降。期內綜合淨利潤的估計並未考慮因今年6月24的公告所披露的停止生產順酐和搬遷生產線對集團資產的任何影響,因在完成獨立評估前,有關常州政府對停止生產和搬遷的補償金額尚未確定。
集團指,財務表現受影響之主要原因是由於今年初COVID-19疫情的爆發,導致客戶需求減弱以,及集團產品平均售價下降導致毛利率下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.